Trial Profile
A Phase III, double-blind, randomized, placebo-controlled study of DYSPORT AESTHETIC for use in the temporary improvement in the appearance of moderate to severe lateral canthal lines (LCLs) at maximum smile
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 04 Sep 2018
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Facial wrinkles
- Focus Registrational; Therapeutic Use
- 04 Sep 2018 New trial record
- 14 Aug 2018 According to a Galderma media release, Health Canada has approved DYSPORT AESTHETIC (abobotulinumtoxinA) for the temporary improvement in the appearance of moderate to severe lateral canthal lines (crow's feet) in adult patients, based on the data from this trial.